# US 2013/0156704 A1 · Therapy for subarachnoid hemorrhage and ischemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156704 A1
- Document ID: US20130156704A1
- Status: Published application
- Kind: A1
- Application number: 13/774,053
- Filed: 2013-02-22
- Published: 2013-06-20
- Earliest claimed: 2011-12-13
- Assignees: NoNO Inc.
- Inventors: Michael Tymianski
- Web page: https://patentgrep.com/patent/US20130156704A1

## CPC

- A61K 38/162: {from virus}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 49/00: Preparations for testing in vivo
- C07K 14/47: from mammals
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C12N 2740/16311: concerning HIV regulatory proteins
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16371: Demonstrated in vivo effect
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.

## Claims

### Claim 1

A method of treating a damaging effect of subarachnoid hemorrhage in a subject, comprising:
administering an agent that inhibits binding of PSD-95 to an NMDAR2 subunit to a subject having a subarachnoid hemorrhage.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subarachnoid hemorrhage is the result of physical trauma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subarachnoid hemorrhage occurs spontaneously.

### Claim 4 (depends on 3)

The method of claim 3, wherein the subarachnoid hemorrhage is due to a ruptured aneurysm.

### Claim 5 (depends on 3)

The method of claim 3, wherein the subarachnoid hemorrhage is due to arteriovenous malformation.

### Claim 6

The method of any preceding claim, wherein the agent inhibits development of neurocognitive deficits in the subject.

### Claim 7

The method of any preceding claim, wherein the agent inhibits development of infarctions detectable by MRI.

### Claim 8

The method of any preceding claim, wherein the subject receives endovascular surgery to repair a ruptured blood vessel causing the subarachnoid hemorrhage.

### Claim 9 (depends on 8)

The method of claim 8, wherein the agent reduces pain resulting from endovascular surgery.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pain is along a path traversed by an endoscope used in performing the endoscopic surgery.

### Claim 11

A method of treating a damaging effect of intracerebral hemorrhage in a subject, comprising
administering an agent that inhibits binding of PSD-95 to an NMDAR2 subunit to a subject having an intracerebral hemorrhage.

### Claim 12 (depends on 11)

The method of claim 11, wherein the intracerebral hemorrhage is due to high blood pressure.

### Claim 13 (depends on 13)

The method of claim 13, wherein the intracerebral hemorrhage is due to a drug.

### Claim 14 (depends on 13)

The method of claim 13, wherein the drug is an anti-coagulant.

### Claim 15

The method of any preceding claim, wherein the agent inhibits development of neurocognitive deficits in the subject.

### Claim 16

The method of any preceding claim, wherein the agent inhibits development of infarcts in the CNS detectable by MRI.

### Claim 17

The method of any preceding claim, wherein the agent is administered before, during or after surgery to repair a blood vessel causing the hemorrhage.

### Claim 18

The method of any preceding claim, wherein the agent is administered before, during or after administering another agent effect to reduce damaging effects of intracerebral hemorrhage.

### Claim 19

The method of any preceding claim, wherein the agent is administered by day 4 post rupture causing the subarachnoid hemorrhage.

### Claim 20

The method of preceding claim, wherein the agent is administered on multiple occasions within twelve days post rupture causing the subarachnoid hemorrhage.

### Claim 21

The method of any preceding claim, wherein the agent is administered twice daily for at least two days or once daily for at least three days.

### Claim 22

The method of any preceding claim wherein the dose of the agent is 1-3 mg/kg.

### Claim 23

An agent that inhibits binding of PSD-95 to an NMDAR2 subunit for use in reducing a damaging effect of ischemia or hemorrhage in or otherwise affecting the CNS of a subject and reducing pain in the subject from surgery to remediate the ischemia or hemorrhage.

### Claim 24 (depends on 23)

The agent of claim 23, wherein the surgery is endovascular surgery.

### Claim 25 (depends on 23)

The agent of claim 23, wherein the pain is along a path traversed by an endoscope used in performing the endoscopic surgery.

### Claim 26

A method of reducing pain, comprising administering an agent that inhibits binding of PSD-95 to an NMDAR2 subunit to a subject receiving endovascular surgery wherein the agent reduces pain in the subject resulting from the endovascular surgery.

### Claim 27 (depends on 26)

The method of claim 26, wherein the pain is along a path traversed by an endoscope used in performing the endoscopic surgery.

### Claim 28

A method of inhibiting a damaging effect of ischemia or hemorrhage in or otherwise affecting the CNS in a subject comprising:
administering to a subject having or suspect of having ischemia or hemorrhage in or otherwise affecting the CNS an effective regime of an agent that inhibits binding of PSD95 to an NMDAR2 subunit, wherein the subject has not been given a scan to distinguish ischemia from hemorrhage when the administering is performed.

### Claim 29 (depends on 28)

The method of claim 28, wherein the subject has a hemorrhage in or otherwise affecting the CNS.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the subject is not subject to reperfusion therapy.

### Claim 31

A method of treating a damaging effect of ischemia or hemorrhage on the central nervous system, comprising administering an agent, which agent inhibits binding of PSD-95 to an NMDAR2 subunit or nNos, to a subject having or at risk of ischemia or hemorrhage.

### Claim 32 (depends on 31)

The method of claim 31, wherein the agent is administered in conjunction with reperfusion therapy, wherein the agent and reperfusion therapy treat a damaging effect of the ischemia on the central nervous system.

### Claim 33 (depends on 31)

The method of claim 31, wherein the subject has or is at risk of ischemia of the central nervous system.

### Claim 34 (depends on 31)

The method of claim 31, wherein the method treats a damaging effect of hemorrhagic stroke.

### Claim 35 (depends on 34)

The method of claim 34, wherein the agent is administered before, during or after endovascular repair of the hemorrhage.

### Claim 36 (depends on 34, 35)

The method of claim 34 or 35, wherein the agent is administered before, during or after treatment with other drugs for the treatment of hemorrhage affecting the central nervous system.

### Claim 37

An agent that inhibits binding of PSD95 to an NMDAR2 subunit for use in treatment of an ischemic stroke that transforms to a hemorrhagic stroke as a result of reperfusion, wherein the agent inhibits damaging effects of the ischemic and hemorrhagic stroke.

### Claim 38

The method or agent of any preceding claim, wherein the agent is a peptide having an amino acid sequence consisting or comprising of X1tSX2V (SEQ ID NO:7), wherein t and S are alternative amino acids, X1 is selected from among E, Q, and A, X2 is selected from among A, Q, D, N, (N-Methyl)-A, (N-methyl)-Q, (N-methyl)-D, and (N-methyl)-N, or the peptide is an agent according to a formula shown below.

### Claim 39 (depends on 38)

The method or agent of claim 38, wherein the peptide is linked to an internalization peptide or is lipidated thereby facilitating passage of the peptide across a cell membrane or the blood brain barrier.

### Claim 40

The method or agent of any preceding claim, wherein the agent is a peptide having an amino acid sequence consisting or comprising of YGRKKRRQRRRKLSSIESDV, SEQ ID NO:6 or YGRKKRRQRRRKLSSIETDV (SEQ ID NO:37).

### Claim 41

The method or agent of any preceding claim wherein the agent is a myristoylated peptide.

### Claim 42 (depends on 41)

The method or agent of claim 41, wherein peptide has an amino acid sequence consisting or comprising of KLSSIESDV or KLSSIETDV.

### Claim 43 (depends on 41, 42)

The method of claim 41 or 42, wherein the myristoylation is at the N-terminus of the peptide.

### Claim 44

A method of screening a compound for activity useful in treating or effecting prophylaxis of stroke or hemorrhage in or otherwise affecting the CNS, comprising:
administering the compound to humans undergoing an endovascular repair procedure affecting the central nervous system, and
determining whether the compound reduces the number of infarcts observed by MRI compared with a negative control.

### Claim 45 (depends on 44)

The method of claim 44, wherein the MRI imaging includes DWI MRI.

### Claim 46 (depends on 44)

The method of claim 44, wherein the MRI imaging includes FLAIR MRI.

### Claim 47 (depends on 44)

The method of claim 44, wherein the MRI imaging includes DWI and FLAIR MRI and infarcts resulting from the endovascular procedure are determined by identifying infarcts present on both DWI and FLAIR MRI.

### Claim 48

A method of treating a subject population presenting sign(s) and/or symptom(s) of ischemia, comprising administering an agent, which agent inhibits binding of PSD-95 inhibitor to an NDMAR2 subunit or nNOS, to the subjects; wherein the subjects are analyzed for unacceptable risk of side effects of reperfusion therapy, and subjects without unacceptable risk of side effects receive reperfusion therapy and subjects with unacceptable risk of side effects do not receive reperfusion therapy, optionally wherein the agent is a peptide that inhibits binding of PSD95 to an NDMAR2 subunit or nNOS, and the peptide is linked to an internalization peptide or is lipidated to increase across a cell membrane or the blood brain barrier.

### Claim 49

An isolated peptide having an amino acid sequence consisting or comprising of X1tSX2V (SEQ ID NO:7), wherein t and S are alternative amino acids, X1 is selected from among E, Q, and A, X2 is selected from among A, Q, D, N, (N-Methyl)-A, (N-methyl)-Q, (N-methyl)-D, and (N-methyl)-N, wherein the peptide is lipidated at the N-terminal amino acid.

### Claim 50 (depends on 49)

The isolated peptide of claim 49, wherein the peptide has an amino acid sequence comprising or consisting of KLSSIESDV or KLSSIETDV.

### Claim 51

A method of treating a damaging effect of subarachnoid hemorrhage in a population of subjects, comprising:
administering an agent that inhibits binding of PSD-95 to an NMDAR2 subunit to subjects having a subarachnoid hemorrhage, wherein the damaging effect is reduced in the administered population compared to control subjects not receiving the agent.

### Claim 52 (depends on 51)

The method of claim 51, wherein the damaging effect that is reduced is neuronal cell death or a cognitive deficit.
